223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy

223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy

Bibliographic Details
Main Authors: Yuan Liu, Dylan Martini, T Anders Olsen, Subir Goyal, Sean Evans, Benjamin Magod, Jacqueline Brown, Lauren Yantorni, Greta Russler, Sarah Caulfield, Jamie Goldman, Bassel Nazha, Wayne Harris, Viraj Master, Omer Kucuk
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-8f34627bbcbf40e6b0087f7a434dc6ae
record_format Article
spelling doaj-8f34627bbcbf40e6b0087f7a434dc6ae2020-12-11T10:00:53ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0223223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapyYuan Liu0Dylan Martini1T Anders Olsen2Subir Goyal3Sean Evans4Benjamin Magod5Jacqueline Brown6Lauren Yantorni7Greta Russler8Sarah Caulfield9Jamie Goldman10Bassel Nazha11Wayne Harris12Viraj Master13Omer Kucuk142Emory University, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA2Emory University, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA3Winship Cancer Institute of Emory University, Atlanta, GA, USA3Winship Cancer Institute of Emory University, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA1Emory University School of Medicine, Atlanta, GA, USA
collection DOAJ
language English
format Article
sources DOAJ
author Yuan Liu
Dylan Martini
T Anders Olsen
Subir Goyal
Sean Evans
Benjamin Magod
Jacqueline Brown
Lauren Yantorni
Greta Russler
Sarah Caulfield
Jamie Goldman
Bassel Nazha
Wayne Harris
Viraj Master
Omer Kucuk
spellingShingle Yuan Liu
Dylan Martini
T Anders Olsen
Subir Goyal
Sean Evans
Benjamin Magod
Jacqueline Brown
Lauren Yantorni
Greta Russler
Sarah Caulfield
Jamie Goldman
Bassel Nazha
Wayne Harris
Viraj Master
Omer Kucuk
223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
Journal for ImmunoTherapy of Cancer
author_facet Yuan Liu
Dylan Martini
T Anders Olsen
Subir Goyal
Sean Evans
Benjamin Magod
Jacqueline Brown
Lauren Yantorni
Greta Russler
Sarah Caulfield
Jamie Goldman
Bassel Nazha
Wayne Harris
Viraj Master
Omer Kucuk
author_sort Yuan Liu
title 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
title_short 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
title_full 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
title_fullStr 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
title_full_unstemmed 223 Racial differences in outcomes for metastatic renal cell carcinoma (mRCC) patients managed on immune-checkpoint inhibitor (ICI) therapy
title_sort 223 racial differences in outcomes for metastatic renal cell carcinoma (mrcc) patients managed on immune-checkpoint inhibitor (ici) therapy
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT yuanliu 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT dylanmartini 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT tandersolsen 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT subirgoyal 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT seanevans 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT benjaminmagod 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT jacquelinebrown 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT laurenyantorni 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT gretarussler 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT sarahcaulfield 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT jamiegoldman 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT basselnazha 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT wayneharris 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT virajmaster 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
AT omerkucuk 223racialdifferencesinoutcomesformetastaticrenalcellcarcinomamrccpatientsmanagedonimmunecheckpointinhibitoricitherapy
_version_ 1724386687009685504

Similar Items